Author

Xieran Li

Observed names: Li, Xieran, X Li

Institution: Medac (Germany)

Observed institution: Medac (Germany)

ORCID: 0000-0002-1443-4032

Observed ORCID: 0000-0002-1443-4032

OpenAlex ID: A5084675762

Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial

2023 · Karl-Walter Sykora, Rita Beier, et al. · Bone Marrow Transplantation · 30

Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data

2024 · Matthias Stelljes, Katja Sockel, et al. · Bone Marrow Transplantation · 5

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial

2026 · Friedrich Stölzel, Matthias Stelljes, et al. · Haematologica · 4

Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation

2023 · Xieran Li, Krzysztof Kalwak, et al. · Drug Metabolism and Pharmacokinetics · 3

Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trials

2024 · Krzysztof Kalwak, Ajay Vora, et al. · British Journal of Clinical Pharmacology · 1

[Fertility analyses of patients with hematologic diseases after allogeneic hematopoietic stem cell transplantation].

2019 · X C Song, N X Song, et al. · PubMed Central

Works count: 7

Citation count: 43

H-index: 3

I10-index: 1